<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02800148</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-16-009</org_study_id>
    <nct_id>NCT02800148</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perrigo Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DPT Laboratories, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Perrigo Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the bioequivalence of Perrigo's azelaic acid foam product to Finacea Foam for the
      treatment of Inflammatory Lesions of Rosacea
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction of lesion count from Day 1</measure>
    <time_frame>Day 84</time_frame>
    <description>Description</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">665</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Azelaic acid foam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Finacea Foam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Foam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic acid foam</intervention_name>
    <arm_group_label>Azelaic acid foam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic acid foam</intervention_name>
    <arm_group_label>Finacea Foam</arm_group_label>
    <other_name>Finacea Foam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic acid foam - Placebo</intervention_name>
    <arm_group_label>Placebo Foam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must sign an Institutional Review Board (IRB) approved written informed
             consent for this study.

          2. Subjects must be at least 18 years of age.

          3. Subjects must have a definite clinical diagnosis of moderate to facial papulopustular
             rosacea,

          4. Subjects must be willing and able to understand and comply with the requirements of
             the study, apply the medication as instructed, refrain from use of all other

          5. Subjects must be in general good health and free from any clinically significant
             disease, other than rosacea, that might interfere with the study evaluations.

          6. Females of childbearing potential (excluding women who are surgically sterilized
             (verified tubal ligation or bilateral oophorectomy or hysterectomy) or post-
             menopausal for at least 2 years), in addition to having a negative urine pregnancy
             test at Visit 1/Day 1 (Baseline), must be willing to use an acceptable form of birth
             control during the study.

        Exclusion Criteria:

          1. Subjects, who are pregnant, breastfeeding, or planning a pregnancy within the period
             of their study participation.

          2. Current or past ocular rosacea

          3. Presence of any other facial skin condition that might interfere with rosacea
             diagnosis and/or assessment

          4. Any uncontrolled, chronic or serious disease or medical condition that would prevent
             participation in a clinical trial or, in judgment of the Investigator, would put the
             subject at undue risk or might confound the study assessments

          5. Currently using any product containing Azelaic Acid/or belonging to the same family as
             Azelaic Acid foam, 15%.

          6. Any use of Azelaic Acid Foam, 15%, 1 month (30 days) prior to baseline or throughout
             the study.

          7. History of hypersensitivity or allergy to FinaceaÂ® (Azelaic Acid) Foam, 15%, and/or
             any ingredient in the study medication.

          8. Use of radiation therapy and/or anti-neoplastic agents within 90 days prior to Visit
             1/Day 1 (Baseline).

          9. Current use of anticoagulation therapy and use throughout the study.

         10. Use of medicated make-up (including anti-aging make-up) throughout the study

         11. Use during the study of 1) systemic steroids, 2) topical retinoids to the face 3)
             antibiotics known to impact rosacea 4) immunosuppressive agents, or immunomodulators).

         12. Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical
             antimycotics, 4) any topical rosacea treatments or 4) topical antibiotics.

         13. Use of medicated cleansers on the face throughout the study.

         14. Subject consumes excessive alcohol, abuses drugs, or has a condition that could
             compromise the subject's ability to comply with study requirements

         15. Use of topical astringents or abrasives, medicated topical preparations (prescription
             and OTC products) within 2 days prior to Visit 1 and throughout the study.

         16. Use of antipruritics (including antihistamines), spa treatments or chlorine exposure
             (swimming etc.) within 24 hours of all study visits.

         17. Participation in any clinical study involving an investigational product, agent or
             device that might influence the intended effects or mask the side effects of study
             medication in the 1 month (30 days) prior Visit 1/Day 1 (Baseline) or throughout the
             study.

         18. Previous enrollment in this study or current enrollment in this study at another
             participating site.

         19. Use of tanning booths, sun lamps (excessive UV radiation e.g., phototherapy, daily
             extended exposure or occupational exposure to the sun), sunbathing or excessive
             exposure to the sun 1 week prior to baseline and throughout the study.

         20. Subjects who in the opinion of the investigator, are unlikely to be able to follow the
             restrictions of the protocol and complete the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dermatology Consultants</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2016</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

